Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

BACKGROUND: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A (CYP3A) isoenzymes, including CYP3A5, in order to be active. It is controversial whether clopidogrel interacts with CYP3A inhibitors. We investigated the influence of CYP3A5 polymorphism on the drug interaction of clopid...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Suh, Jung-Won, Koo, Bon-Kwon, Zhang, Shu-Ying, Park, Kyung-Woo, Cho, Joo-Youn, Jang, In-Jin, Lee, Dong-Soon, Sohn, Dae-Won, Lee, Myoung-Mook, Kim, Hyo-Soo
Format: Artigo
Jezik:Inglês
Izdano: Canadian Medical Association 2006
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1471813/
https://ncbi.nlm.nih.gov/pubmed/16754899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/cmaj.060664
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items